Short Communication| Volume 209, ISSUE 1-2, P50-52, January 2016

Download started.


The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil

      In Brazil, several recurring mutations in BRCA1 and BRCA2 and a TP53 mutation (R337H) have been reported in high risk breast cancer cases. We hypothesized that these recurring mutations may also be detected in the general population and ovarian cancer cases in the state of Minas Gerais. To test this notion, participants were recruited from the outpatient and the Gynecological clinic in the UFMG Medical Center in Belo Horizonte, Minas Gerais, Brazil. BRCA1 (c.68_69delAG, c.5266dupC, c.181T>G, c.4034delA, c.5123C>A), BRCA2 (c.5946delT, c.8537_8538delAG, 4936_4939delGAAA), the c.156_157insAlu* BRCA2 and the c.1010G>A *TP53 mutation were genotyped using validated techniques. Overall, 513 cancer free participants (273 men) (mean age 47.7 ± 15.1 years) and 103 ovarian cancer cases (mean age at diagnosis 58.7 ± 9.6 years) were studied. None of the participants were found to carry any of the genotyped mutations. We conclude that the recurring mutations in BRCA1, BRCA2 and TP53 cannot be detected in the general population or consecutive ovarian cancer cases in this geographical region in Brazil.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mavaddat N.
        • Antoniou A.C.
        • Easton D.F.
        • et al.
        Genetic susceptibility to breast cancer.
        Mol Oncol. 2010; 4: 174-191
        • McBride K.A.
        • Ballinger M.L.
        • Killick E.
        • et al.
        Li-Fraumeni syndrome: cancer risk assessment and clinical management.
        Nat Rev Clin Oncol. 2014; 11: 260-271
        • Stuckey A.R.
        • Onstad M.A.
        Hereditary breast cancer: an update on risk assessment and genetic testing in 2015.
        Am J Obstet Gynecol. 2015; 213: 161-165
        • Roa B.B.
        • Boyd A.A.
        • Volcik K.
        • et al.
        Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
        Nat Genet. 1996; 14: 185-187
        • Moslehi R.
        • Chu W.
        • Karlan B.
        • et al.
        BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
        Am J Hum Genet. 2000; 66: 1259-1272
        • Ashton-Prolla P.
        • Vargas F.R.
        Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.
        Genet Mol Biol. 2014; 37: 234-240
        • Moreira M.A.
        • Bobrovnitchaia I.G.
        • Lima M.A.
        • et al.
        Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype.
        Fam Cancer. 2012; 11: 657-660
        • Manchanda R.
        • Loggenberg K.
        • Sanderson S.
        • et al.
        Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
        J Natl Cancer Inst. 2014; 107: 379-393

      Linked Article